Literature DB >> 19347879

In prostate cancer C/EBPalpha promotes cell growth by the loss of interactions with CDK2, CDK4, and E2F and by activation of AKT.

Hong Yin1, Mary Lowery, Jonathan Glass.   

Abstract

BACKGROUND: The CCAAT/Enhancer binding protein alpha (C/EBPalpha) is an important transcription factor for granulopoiesis and adipogenesis. While decreased expression and mutation of C/EBPalpha has been found in several types of tumors, the role of C/EBPalpha in prostate cancer has not been well characterized.
METHODS: We quantitatively analyzed the immunochemical staining of prostate cancer tissue and examined the growth properties of prostate cancer cells stably expressing C/EBPalpha by measure growth curve, cell cycle, and anchorage independent colony formation, investigated the association of C/EBPalpha with E2Fs and CDKs by co-immunoprecipitation and examined the expression of CDKs and activation of AKT by Western blot analysis.
RESULTS: The ratio of C/EBPalpha expression between cancer cells close to the pseudolumen of glands and those nearer the basal cell layer was more than threefold greater than that seen in the normal prostate epithelium. Further, this ratio increased with increased Gleason score of the prostate cancer. Forced expression of C/EBPalpha in prostate cancer cell lines accelerated cell growth, stimulated cells into the S and G2 phases of cell cycle, and enhanced anchorage-independent colony formation. Simultaneously, forced expression of C/EBPalpha increased expression of CDK2/CDK4 and nuclear PP2A, and activated AKT. In addition, C/EBPalpha was no longer found associated with E2F1/E2F4 and CDK2/CDK4. AKT and PPA2 inhibitors restored both the anti-proliferation function of C/EBPalpha and the interaction between C/EBPalpha and E2F1/E2F4.
CONCLUSION: In prostate cancer cells C/EBPalpha cannot function as a tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19347879     DOI: 10.1002/pros.20947

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Authors:  Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  C/EBPα, C/EBPα oncoproteins, or C/EBPβ preferentially bind NF-κB p50 compared with p65, focusing therapeutic targeting on the C/EBP:p50 interaction.

Authors:  Julia E Dooher; Ido Paz-Priel; Simone Houng; Albert S Baldwin; Alan D Friedman
Journal:  Mol Cancer Res       Date:  2011-08-03       Impact factor: 5.852

Review 3.  A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood.

Authors:  A R Lourenço; P J Coffer
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

Review 4.  Intracellular signaling and hepatocellular carcinoma.

Authors:  Polina Iakova; Lubov Timchenko; Nikolai A Timchenko
Journal:  Semin Cancer Biol       Date:  2010-09-17       Impact factor: 15.707

5.  CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma.

Authors:  Guo-Dong Lu; Yang Huey Ang; Jing Zhou; Jegadeesan Tamilarasi; Benedict Yan; Yaw Chyn Lim; Supriya Srivastava; Manuel Salto-Tellez; Kam M Hui; Han-Ming Shen; Long N Nguyen; Bryan C Tan; David L Silver; Shing Chuan Hooi
Journal:  Hepatology       Date:  2015-01-30       Impact factor: 17.425

6.  The significance of c.690G>T polymorphism (rs34529039) and expression of the CEBPA gene in ovarian cancer outcome.

Authors:  Bozena Konopka; Lukasz Michal Szafron; Ewa Kwiatkowska; Agnieszka Podgorska; Aleksandra Zolocinska; Barbara Pienkowska-Grela; Agnieszka Dansonka-Mieszkowska; Anna Balcerak; Martyna Lukasik; Anna Stachurska; Agnieszka Timorek; Beata Spiewankiewicz; Mona El-Bahrawy; Jolanta Kupryjanczyk
Journal:  Oncotarget       Date:  2016-10-11

7.  Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.

Authors:  Jiehua Zhou; Haitang Li; Xin Xia; Alberto Herrera; Nicolette Pollock; Vikash Reebye; Mikael H Sodergren; Stephanie Dorman; Bruce H Littman; Declan Doogan; Kai-Wen Huang; Robert Habib; David Blakey; Nagy A Habib; John J Rossi
Journal:  Mol Ther       Date:  2019-02-26       Impact factor: 11.454

8.  hMSCs Migrate under the Chemotaxis of CXCL-13 and Enhance Islet B Cell Activity through p-AKT Signaling Pathway in High-Glucose Environment.

Authors:  Yongtao Li; Wenshan Bian; Yang Jiang; Danyang Liu; Lei Shen
Journal:  J Healthc Eng       Date:  2022-01-07       Impact factor: 2.682

9.  Comprehensive bioinformatics analysis of the E2F family in human clear cell renal cell carcinoma.

Authors:  Zhi-Guo Liu; Jing Su; Hao Liu; Xue-Jian Yang; Xue Yang; Ye Wei; Xin-Yao Zhu; Yong Song; Xian-Cheng Zhao; Hong-Lin Guo
Journal:  Oncol Lett       Date:  2022-08-19       Impact factor: 3.111

Review 10.  Exosomes of pasteurized milk: potential pathogens of Western diseases.

Authors:  Bodo C Melnik; Gerd Schmitz
Journal:  J Transl Med       Date:  2019-01-03       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.